Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
May 10, 2023 16:15 ET
|
Cingulate Inc.
Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS...
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
May 03, 2023 06:45 ET
|
Cingulate Inc.
KANSAS CITY, Kan., May 03, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in Benzinga All Live Access Event
April 14, 2023 14:00 ET
|
Cingulate Inc.
KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD
April 04, 2023 06:45 ET
|
Cingulate Inc.
Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:...
Thor Equities Group Chairman, Joe Sitt, Makes Guest Appearance on Bloomberg Markets to Discuss Current Real Estate Trends and Shares Insights on Investment Strategies During a War Economy
March 24, 2023 12:16 ET
|
Thor Equities Group
New York, March 24, 2023 (GLOBE NEWSWIRE) -- Joe Sitt, Chairman of leading global real estate firm, Thor Equities Group, spoke on Bloomberg Markets on March 23rd to discuss the highlights and...
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 13, 2023 06:45 ET
|
Cingulate Inc.
Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in...
Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
March 10, 2023 16:05 ET
|
Cingulate Inc.
CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming...
New to The Street Announces the Televised Lineups for Shows 441, 442, and 443, Airings on Three Networks Will Begin on Saturday, February 25, 2023, 3:30 PM ET
February 24, 2023 15:16 ET
|
FMW Media Works Corp
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a premier business television show, announces their featured guests' lineups on shows 441, 442, and 443. Each show to air...
Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHD
February 23, 2023 16:30 ET
|
Cingulate Inc.
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) --...
Old National Named to 2023 Bloomberg Gender-Equality Index
February 09, 2023 16:59 ET
|
Old National Bancorp
EVANSVILLE, Ind., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Old National Bancorp is pleased to announce that it is a member of the 2023 Bloomberg Gender-Equality Index (GEI) for the third consecutive year,...